DISCUVA LIMITED
Get an alert when DISCUVA LIMITED files next
Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.
Next accounts due
2026-09-30 (in 4mo)
Last filed for 2024-12-31
Confirmation statement due
2026-04-02
Overdue
Watchouts
Cash
£216K
-89.5% vs 2023
Net assets
£77K
-97.5% vs 2023
Employees
—
Average over period
Profit before tax
-£402K
+76.6% vs 2023
Watchouts
Facts from the Companies House register and the latest accounts — not a rating
-
Confirmation statement overdue
Due 2026-04-02.
-
Material uncertainty over going concern
The financial information in these financial statements has been prepared on a going concern basis due to the continued financial support of the ultimate parent company, Summit Therapeutics Inc. and the cash held by the Company. The Directors have received confirmation that Summit Therapeutics Inc. intends to support the Company for at least 12 months from the date of approval of these financial statements. As noted in the Summit Therapeutics Inc. unaudited condensed consolidated financial statements for the 6-months ended 30 June 2025, the Group's cash and cash equivalents are not sufficient to fund the planned operations for a period of at least one year from the date those financial statements were issued on 11 August 2025. The Group has disclosed that these conditions raise substantial doubt over its ability to continue as a going concern.
Name history
Renamed 1 time since incorporation
- DISCUVA LIMITED 2011-01-10 → present
- OMACROM LIMITED 2007-03-19 → 2011-01-10
Net assets
2-year trend · vs Health Care median
Accounts
2-year trend · latest reflected 2024-12-31
| Metric | Trend | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Turnover | — | — | |
| Operating profit | -£1,705,268 | -£402,447 | |
| Profit before tax | -£1,718,556 | -£402,447 | |
| Net profit | -£1,589,410 | -£397,657 | |
| Cash | £2,053,527 | £215,995 | |
| Total assets less current liabilities | £3,108,690 | £77,224 | |
| Net assets | £3,108,690 | £77,224 | |
| Equity | £3,108,690 | £77,224 | |
| Average employees | 4 | — | |
| Wages | £579,525 | — |
Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers
Ratios
Computed from the line items above — sparklines read oldest → newest
| Ratio | Trend | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Return on capital employed | -54.9% | -521.1% | |
| Current ratio | 34.68x | 1.29x | |
| Interest cover | -128.33x | — |
Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.
Audit & accounting basis
- Accounting basis
- FRS 101
- Reporting scope
- Standalone (parent only)
- Auditor
- PricewaterhouseCoopers LLP
- Audit opinion
- Unqualified (clean)
- Going concern
- Material uncertainty disclosed
“The financial information in these financial statements has been prepared on a going concern basis due to the continued financial support of the ultimate parent company, Summit Therapeutics Inc. and the cash held by the Company. The Directors have received confirmation that Summit Therapeutics Inc. intends to support the Company for at least 12 months from the date of approval of these financial statements. As noted in the Summit Therapeutics Inc. unaudited condensed consolidated financial statements for the 6-months ended 30 June 2025, the Group's cash and cash equivalents are not sufficient to fund the planned operations for a period of at least one year from the date those financial statements were issued on 11 August 2025. The Group has disclosed that these conditions raise substantial doubt over its ability to continue as a going concern.”
Significant events
- “During 2023, the Summit Therepeutics Inc. Group reprioritised its investments and financial resources from anti-infectives towards oncology development, leading to Discuva's research and development costs reducing significantly.”
- “The Company completed capital reduction activities during the year ended 31 December 2024, resulting in a dividend of £2,633,809 being declared to the immediate parent, Summit Therapeutics Limited.”
- “The Company's headcount was reduced to nil as of 31 December 2023, and employee and related costs were £nil for the year ended 31 December 2024.”
Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers
People
3 active · 21 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| ANAND, Bhaskar | Director | 2024-04-17 | Jun 1977 | American |
| DUGGAN, Robert William | Director | 2020-05-27 | Apr 1944 | American |
| SONI, Manmeet Singh | Director | 2023-12-06 | Nov 1977 | American |
Show 21 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| O'NEILL, Hugh Feargal | Secretary | 2020-06-30 | 2021-06-08 |
| STRANGE, Melissa Claire | Secretary | 2017-12-23 | 2020-06-30 |
| WILLIAMS, Deirdre Lesley Joyce | Secretary | 2007-03-19 | 2011-10-31 |
| SDG SECRETARIES LIMITED | Corporate Nominee Secretary | 2007-03-19 | 2007-03-19 |
| BULLOCK, Timothy Charles | Director | 2011-12-02 | 2017-12-23 |
| DHINGRA, Ankur | Director | 2022-08-18 | 2024-04-02 |
| DUGGAN, Robert William | Director | 2020-06-05 | 2020-06-05 |
| DUGGAN, Robert William | Director | 2020-05-27 | 2020-06-05 |
| EDWARDS, Glyn Owain | Director | 2017-12-23 | 2020-06-05 |
| GEORGE, Ian Michael Riorden, Dr | Director | 2011-12-02 | 2017-12-23 |
| HAIR, Campbell | Director | 2021-12-06 | 2022-08-10 |
| MARANIAN, Jeffrey | Director | 2021-12-06 | 2022-01-21 |
| NEWEY, Paul Anthony | Director | 2012-12-20 | 2014-02-26 |
| NEY, Ursula Mary, Dr | Director | 2016-03-23 | 2017-12-23 |
| POWELL, David Jonathan, Dr. | Director | 2021-01-29 | 2021-11-26 |
| REGGIANI, Ernesto Giorgio | Director | 2011-12-02 | 2017-12-23 |
| STEFANOV, Ventzislav Kirilov, Dr | Director | 2020-06-05 | 2020-06-05 |
| STEFANOV, Ventzislav Kirilov, Dr | Director | 2020-05-27 | 2020-12-04 |
| WAIN, John Richard | Director | 2011-12-02 | 2017-12-23 |
| WILLIAMS, David Hugh, Dr | Director | 2007-03-19 | 2017-12-23 |
| SDG REGISTRARS LIMITED | Corporate Nominee Director | 2007-03-19 | 2007-03-19 |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| Summit Therapeutics Limited | Corporate entity | Shares 75–100%, Voting 75–100%, Appoints directors | 2017-12-23 | Active |
| New Wave Ventures Llp | Corporate entity | Shares 50–75%, Voting 25–50% | 2016-04-06 | Ceased 2017-12-23 |
Filing timeline
Last 20 of 142 total filings
Material constitutional events — rename, articles re-file, resolution
- 2024-03-12 RESOLUTIONS Resolution
- 2024-03-12 RESOLUTIONS Resolution
- 2024-03-11 RESOLUTIONS Resolution
| Date | Type | Category | Description | |
|---|---|---|---|---|
| 2025-10-22 | AA | accounts | Accounts with accounts type full | |
| 2025-04-02 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2024-09-28 | AA | accounts | Accounts with accounts type full | |
| 2024-04-26 | AP01 | officers | Appoint person director company with name date | |
| 2024-04-25 | TM01 | officers | Termination director company with name termination date | |
| 2024-03-19 | CS01 | confirmation-statement | Confirmation statement with updates | |
| 2024-03-12 | SH19 | capital | Capital statement capital company with date currency figure | |
| 2024-03-12 | SH20 | capital | Legacy | |
| 2024-03-12 | CAP-SS | insolvency | Legacy | |
| 2024-03-12 | RESOLUTIONS | resolution | Resolution | |
| 2024-03-12 | SH01 | capital | Capital allotment shares | |
| 2024-03-12 | SH19 | capital | Capital statement capital company with date currency figure | |
| 2024-03-12 | SH20 | capital | Legacy | |
| 2024-03-12 | CAP-SS | insolvency | Legacy | |
| 2024-03-12 | RESOLUTIONS | resolution | Resolution | |
| 2024-03-11 | SH01 | capital | Capital allotment shares | |
| 2024-03-11 | SH19 | capital | Capital statement capital company with date currency figure | |
| 2024-03-11 | SH20 | capital | Legacy | |
| 2024-03-11 | CAP-SS | insolvency | Legacy | |
| 2024-03-11 | RESOLUTIONS | resolution | Resolution |
Public-record activity
Raw counts from Companies House — last 12–24 months
- Filings
- 1
- Capital events
- 0
- Officers appointed
- 0
- Officers resigned
- 0
last 12 months
last 24 months
last 12 months
last 12 months
Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.
Year-on-year
FY2023 → FY2024 · period ending 2024-12-31 vs 2023-12-31
-
Turnover
—
Not reported
-
Cash
-89.5%
£2,053,527 £215,995
-
Net assets
-97.5%
£3,108,690 £77,224
-
Employees
—
Not reported
-
Operating profit
+76.4%
-£1,705,268 -£402,447
-
Profit before tax
+76.6%
-£1,718,556 -£402,447
Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers